The transaction if completed would have positioned the Hyderabad-based
firm as the second largest dermatology player and the second largest
generics company in the US by prescriptions.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/aurobindo-sandoz-call-off-usd-900-mn-deal/articleshow/74945611.cms
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment